Modern Health

Revenue, headcount, and customer-count figures come from third-party databases and use different scope definitions. The valuation line reflects the last disclosed financing mark, not necessarily fair value on the run date.

Governance data is only partially public. The table focuses on leaders and investor voices confirmed in official or accessible secondary materials rather than claiming full board composition.

Earlier rounds are database reconstructions rather than primary financing documents. Treat the 2021 Series D as the strongest public anchor and later valuation figures as secondary estimates.

This map focuses on disclosed capital and channel stakeholders that visibly affect governance, distribution, or financing context; it is not a full cap table.

Dates after 2021 rely on the publication vintages of accessible company or mirrored sources. The table emphasizes milestones with public evidence rather than attempting an exhaustive internal product-release log.

This table intentionally narrows the market to employer-sponsored workforce behavioral health instead of treating all behavioral health or all mental health apps as interchangeable.

The strongest use of these figures is directional sizing and segmentation logic, not a single plug-in TAM for valuation modeling.

The market is structurally split between economic buyers and end users, which is why outcome reporting, privacy boundaries, and adoption design matter simultaneously.

Modern Health's market tailwinds are real, but multiple drivers are double-edged and can increase both opportunity and operating complexity.

Scale and valuation fields mix official company claims, Tracxn market-data estimates, and public market data. The goal is competitive positioning, not a mark-to-market valuation deck.

This matrix uses relative descriptors rather than false precision because vendors market overlapping capabilities but differ in emphasis, maturity, and proof quality.

The category is intentionally opaque on price. Public signals are more useful for packaging and procurement logic than for exact dollar benchmarking.

These risks are framed from Modern Health's perspective and emphasize which parts of the moat are copyable, contestable, or dependent on execution quality.

Public evidence is strong on revenue mechanism but weak on revenue mix. The table separates observed revenue architecture from values that remain private.

These are contract-market proxies, not audited realized net revenue figures. They are still useful for bounding ACV and pricing power.

Most material unit-economic fields remain private. Public evidence is sufficient to frame the asks precisely, not to answer them definitively.

None of these gaps is cosmetic. Together they determine whether Modern Health deserves a software-like, services-like, or blended valuation framework.

Historical funding is visible; present liquidity is not. That asymmetry is the central capital adequacy blocker in this chapter.

Public evidence is strongest on module existence and intended use, weaker on utilization, margins, and exact regional availability.

The product attempts to solve both access and routing problems, which is broader than a point teletherapy workflow.

Architecture details are inferred from engineering job descriptions and support flows, not from a company-published system diagram.

This is a release-signal table, not a formal roadmap. Public evidence shows directionality, not a complete product plan.

Trust evidence exists, but much of it is policy-level rather than independently attested.

Public segmentation evidence is strongest for multinational employers and technology-led buyers, but case studies also show traction in banking, education, and trust-style member populations.

Publicly named customers are only a subset of the installed base. The evidence quality varies from detailed launch/outcome proof to lighter logo or quote-level confirmation.

This table mixes company-wide breadth signals with deployment-level adoption metrics because Modern Health does not publish a single reconciled adoption time series.

Satisfaction and outcome points exist, but public retention disclosure is effectively absent. This is the central durability gap in the customer chapter.

The visible expansion mechanisms are credible, but the two most material unresolved risks are concentration and retention opacity.

Ordered by public severity for this report. The table focuses on legal and regulatory vectors most likely to transmit into customer or financing damage.

The core operational risk is not a single outage; it is the interaction of provider capacity, triage quality, and data security in a high-sensitivity care environment.

Several of Modern Health's most material dependencies are not suppliers in the narrow sense; they are whole ecosystems whose failure can impair delivery, economics, or trust.

Execution risk matters because the company sells a high-trust benefit, where operational mistakes are felt directly by employers, members, and regulators.

These triggers are designed to be decision-useful. They convert broad risk themes into specific diligence asks and re-underwriting thresholds.

This table is deliberately decision-oriented rather than celebratory. The recommendation is based on price relative to disclosed proof, not on whether Modern Health is an attractive product.

The most important anti-thesis is not that the category is bad. It is that Modern Health may be good while still being fully priced.

Entry discipline should start with these anchors, then move immediately into private diligence.

Scenario ranges use public revenue estimates and multiple discipline rather than management guidance. They are valuation bands, not price targets.

No single comparable is sufficient. The value comes from using direct private peers for category relevance and public comps for pricing discipline.

Exit thinking matters because the current valuation can only be rationalized if there is a believable path to durable financing leverage or credible strategic scarcity.

These triggers are meant to be monitorable and investment-useful, not generic risk statements.

If management cannot supply this package, the recommendation should remain track or move lower even if topline growth is attractive.